Please login to the form below
Kevzara
This page shows the latest Kevzara news and features for those working in and with pharma, biotech and healthcare.
EMA to evaluate Roche arthritis drug RoActemra for severe COVID-19
Along with Sanofi's Kevzara, Roche’s Actemra was recommended in the World Health Organization’s updated patient care guidelines as a ‘life-saving’ drug for the treatment of COVID-19
Latest news
-
WHO recommends ‘life-saving’ IL-6 inhibitors for severe COVID-19
Roche's Actemra and Sanofi's Kevzara are included in WHO's updated patient care guidelines. ... Both Actemra and Kevzara are IL-6 receptor agonists and are most commonly used to treat anti-inflammatory conditions, including arthritis.
-
Roche’s anti-inflammatory drug reduces deaths in hospitalised COVID-19 patients
Results from the REMAP-CAP trial found that tocilizumab, as well as Sanofi’s Kevzara (sarilumab), reduced mortality by 8.6%, and also improved recovery times among patients who are critically
-
UK study finds antibiotics azithromycin and doxycycline ineffective against COVID-19
Earlier this month, a study led by Imperial College London, known as REMAP-CAP, found that Roche’s Actemra (tocilizumab) and Sanofi’s Kevzara (sarilumab) cut the risk of death in ... This trial found that both Actemra and Kevzara reduced mortality by
-
Two drugs found to reduce mortality in severe COVID-19 patients
Actemra and Kevzara also improved recovery times among critically ill COVID-19 patients. ... Both Actemra and Kevzara are IL-6 receptor agonists and are most commonly used to treat anti-inflammatory conditions, including arthritis.
-
Novartis’ canakinumab failed to improve survival in COVID-19 study
This includes Roche’s Actemra (tocilizumab) and Sanofi and Regeneron’s Kevzara (sarilumab), with both drugs entering clinical trials evaluating their efficacy in severely ill COVID-19 patients. ... Kevzara was also unable to prevent death or help
More from news
Approximately 7 fully matching, plus 27 partially matching documents found.
Latest Intelligence
-
As COVID-19 takes over the world, biopharma fights back
Evaluating IL-6 inhibitors: Roche’s Actemra and Sanofi and Regeneron’s Kevzara. Roche, Sanofi and Regeneron are also looking to repurpose their existing treatments and are currently testing their ... Encouraged by this initial data, Sanofi and
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Sanofi Global Health unveils new nonprofit Impact brand
- Novartis announces positive phase 3 trial results for advanced oesophageal cancer
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- My journey advancing the science in pulmonary hypertension
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- The Power of AI in Medical Education
- First evidence-based guide launched to put patients at heart of digital innovations
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- New Swiss research reveals how Omicron evades the immune system
- Evoke Kyne Named Communiqué Communications Consultancy of the Year 2021
- Michael Grela Elected President of the Society for Health Communication
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- A creative awakening – how pharma is bringing innovation to the patient journey
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses
- Shionogi Europe and NHS England agree on antibiotic subscription model
PMHub
Streaming Well
Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...
Latest intelligence
- Five big changes in the healthcare comms landscape
- The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
- Early communications in Pharma: How effective pre-approval comms delivers launch success
- What communications are required for a successful launch...
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
